Search

Your search keyword '"Musialek, Piotr"' showing total 8 results
Start Over Author "Musialek, Piotr" Journal international journal of cardiology
8 results on '"Musialek, Piotr"'

1. Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial

Author

Paraskevas, Kosmas I., Spence, J. David, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Gloviczki, Peter, Eckstein, Hans-Henning, Spinelli, Francesco, Stilo, Francesco, Saba, Luca, Poredos, Pavel, Dardik, Alan, Liapis, Christos D., Mansilha, Armando, Faggioli, Gianluca, Pini, Rodolfo, Jezovnik, Mateja K., Sultan, Sherif, Musiałek, Piotr, Goudot, Guillaume, Lavenson, George S., Jr, Jawien, Arkadiusz, Blinc, Aleš, Myrcha, Piotr, Fernandes e Fernandes, Jose, Geroulakos, George, Kakkos, Stavros K., Knoflach, Michael, Proczka, Robert M., Capoccia, Laura, Rundek, Tatjana, Svetlikov, Alexei S., Silvestrini, Mauro, Ricco, Jean-Baptiste, Davies, Alun H., Di Lazzaro, Vincenzo, Suri, Jasjit S., Lanza, Gaetano, Fraedrich, Gustav, Zeebregts, Clark J., and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

3. The Virtual histology In CaroTids Observational RegistrY (VICTORY) study: A European prospective registry to assess the feasibility and safety of intravascular ultrasound and virtual histology during carotid interventions

Author

Sangiorgi, Giuseppe, Bedogni, Francesco, Sganzerla, Paolo, Binetti, Giorgio, Inglese, Luigi, Musialek, Piotr, Esposito, Giovanni, Cremonesi, Alberto, Biasi, Giorgio, Jakala, Jacek, Mauriello, Alessandro, and Biondi-Zoccai, Giuseppe

Published
2013
Full Text
View/download PDF

4. A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute stemi patients undergoing primary PCI

Author

Dhil, David Adlam, primary, Zarebinski, Maciej, additional, Uren, Neal G., additional, Ptaszynski, Pawel, additional, Oldroyd, Keith G., additional, Munir, Shahzad, additional, Zaman, Azfar, additional, Contractor, Hussain, additional, Kiss, Róbert Gábor, additional, Édes, István, additional, Szachniewicz, Joanna, additional, Nagy, Gergely Gyorgy, additional, Garcia, Mario J., additional, Tomcsanyi, János, additional, Irving, John, additional, Sharp, Andrew S.P., additional, Musialek, Piotr, additional, Lupkovics, Géza, additional, Shirodaria, Cheerag, additional, Selvanayagam, Joseph B., additional, Quinn, Pauline, additional, Ng, Leong, additional, Roth, Mark, additional, Insko, Michael A., additional, Haber, Ben, additional, Hill, Stephen, additional, Siegel, Lori, additional, Tulloch, Simon, additional, and Channon, Keith M., additional

Published
2021
Full Text
View/download PDF

5. Clarifying the rationale supporting selective screening for asymptomatic carotid artery stenosis

Author

Paraskevas, Kosmas I., Nicolaides, Andrew N., Spence, J. David, Mikhailidis, Dimitri P., Lanza, Gaetano, Liapis, Christos D., Goudot, Guillaume, Faggioli, Gianluca, Pini, Rodolfo, Musiałek, Piotr, Suri, Jasjit S., Silvestrini, Mauro, Fernandes e Fernandes, Jose, Eckstein, Hans-Henning, Jawien, Arkadiusz, Spinelli, Francesco, Stilo, Francesco, Myrcha, Piotr, Rundek, Tatjana, Kakkos, Stavros K., Di Lazzaro, Vincenzo, Svetlikov, Alexei, Antignani, Pier Luigi, Poredos, Pavel, Saba, Luca, Jezovnik, Mateja K., Blinc, Aleš, Sultan, Sherif, Knoflach, Michael, Capoccia, Laura, Proczka, Robert M., Fraedrich, Gustav, Zeebregts, Clark J., Davies, Alun H., Geroulakos, George, Ricco, Jean-Baptiste, Mansilha, Armando, Dardik, Alan, and Gloviczki, Peter

Published
2023
Full Text
View/download PDF

6. Screening for asymptomatic carotid stenosis in patients with non-valvular atrial fibrillation

Author

Paraskevas, Kosmas I., Eckstein, Hans-Henning, Mansilha, Armando, Ricco, Jean-Baptiste, Geroulakos, George, Di Lazzaro, Vincenzo, Rundek, Tatjana, Lanza, Gaetano, Fraedrich, Gustav, Svetlikov, Alexei S., Suri, Jasjit S., Zeebregts, Clark J., Davies, Alun H., Capoccia, Laura, Proczka, Robert M., Myrcha, Piotr, Antignani, Pier Luigi, Fernandes e Fernandes, Jose, Spence, J. David, Dardik, Alan, Jezovnik, Mateja K., Knoflach, Michael, Lavenson, George S., Jr., Kakkos, Stavros K., Jawien, Arkadiusz, Silvestrini, Mauro, Blinc, Aleš, Spinelli, Francesco, Stilo, Francesco, Musiałek, Piotr, Sultan, Sherif, Goudot, Guillaume, Liapis, Christos D., Saba, Luca, Faggioli, Gianluca, Pini, Rodolfo, Poredos, Pavel, Mikhailidis, Dimitri P., Gloviczki, Peter, and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

8. A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI.

Author

Adlam, David, Zarebinski, Maciej, Uren, Neal G., Ptaszynski, Pawel, Oldroyd, Keith G., Munir, Shahzad, Zaman, Azfar, Contractor, Hussain, Kiss, Róbert Gábor, Édes, István, Szachniewicz, Joanna, Nagy, Gergely Gyorgy, Garcia, Mario J., Tomcsanyi, János, Irving, John, Sharp, Andrew S.P., Musialek, Piotr, Lupkovics, Géza, Shirodaria, Cheerag, and Selvanayagam, Joseph B.

Subjects
*ST elevation myocardial infarction, *MYOCARDIAL infarction, *REPERFUSION injury, *MYOCARDIAL reperfusion, *ARRHYTHMIA, *HEART failure
Abstract

Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfusion injury, which is caused by multiple pathways activated by rapid tissue reoxygenation and the generation of reactive oxygen species (ROS). FDY-5301 contains sodium iodide, a ubiquitous inorganic halide and elemental reducing agent that can act as a catalytic anti-peroxidant. We tested the feasibility, safety and potential utility of FDY-5301 as a treatment to limit ischemia-reperfusion injury, in patients with first-time STEMI undergoing emergency PPCI. STEMI patients (n = 120, median 62 years) presenting within 12 h of chest pain onset were randomized at 20 PPCI centers, in a double blind Phase 2 clinical trial, to receive FDY-5301 (0.5, 1.0 or 2.0 mg/kg) or placebo prior to reperfusion, to evaluate the feasibility endpoints. Participants underwent continuous ECG monitoring for 14 days after PPCI to address pre-specified cardiac arrhythmia safety end points and cardiac magnetic resonance imaging (MRI) at 72 h and at 3 months to assess exploratory efficacy end points. Intravenous FDY-5301 was delivered before re-opening of the infarct-related artery in 97% participants and increased plasma iodide levels ~1000-fold within 2 min. There was no significant increase in the primary safety end point of incidence of cardiac arrhythmias of concern. MRI at 3 months revealed median final infarct sizes in placebo vs. 2.0 mg/kg FDY-5301-treated patients of 14.9% vs. 8.5%, and LV ejection fractions of 53.9% vs. 63.2%, respectively, although the study was not powered to detect statistical significance. In patients receiving FDY-5301, there was a significant reduction in the levels of MPO, MMP2 and NTproBNP after PPCI, but no reduction with placebo. Intravenous FDY-5301, delivered immediately prior to PPCI in acute STEMI, is feasible, safe, and shows potential efficacy. A larger trial is justified to test the effects of FDY-5301 on acute ischemia-reperfusion injury and clinical outcomes. Clinical Trial Registration: CT.gov NCT03470441 ; EudraCT 2017-000047-41 • This phase 2a trial tested intravenous FDY-5301, containing sodium iodide, to prevent IR injury in heart attack patients • FDY-5301 was successfully given within 2 min, before opening the blocked coronary artery • FDY-5301 was safe, with no significant adverse events • FDY-5301 showed promising trends to reduce heart attack damage • This result justify a Phase 3 clinical outcomes trial of FDY-5301 in acute heart attack patients [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results